Biology Reference
In-Depth Information
Greco EA, Spera G, Aversa A (2006) Combining testosterone and PDE5 inhibitors in erectile
dysfunction: basic rationale and clinical evidences. Eur Urol 50:940-947
Guay D, Hamel P, Blouin M, Brideau C, Chan CC, Chauret N, Ducharme Y, Huang Z, Girard M,
Jones TR, Laliberte F, Masson P, McAuliffe M, Piechuta H, Silva J, Young RN, Girard Y
(2002) Discovery of L-791.943: a potent, selective, non-emetic and orally active phosphodies-
terase 4 inhibitor. Bioorg Med Chem Lett 12:1457-1461
Guess HA (1995) Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin
North Am 22:247-261
G
uzel E, Dogantekin E, Kiziltepe G (2008) Does sildenafil affect uroflowmetry values in
men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int
80:181-185
Gur S, Sikka SC, Hellstrom WJ (2008) Novel phosphodiesterase 5 (PDE5) inhibitors in the
alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert
Opin Investig Drugs 17:855-864
Gutierrez P, Hernandez P, Mas M (2005) Combining programmed intracavernous PGE1 injections
and sildenafil on demand to salvage sildenafil non-responders. Int J Impot Res 17:354-358
Han P, Zhu X, Michaeli T (1997) Alternative splicing of the high affinity cAMP-specific
phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem
272:16152-16157
Hatzimouratidis K, Hatzichristou DG (2008) Looking to the future for erectile dysfunction
therapies. Drugs 68:231-250
Heaton JP, Morales A, Owen J (1990) Topical glyceryltrinitrate causes measurable penile arterial
dilatation in impotent men. J Urol 143:729-731
Hieble JR, Ruffolo RR Jr (1996) The use of alpha-adrenoceptor antagonists in the pharmacological
management of benign prostatic hyperplasia: an overview. Pharmacol Res 33:145-160
Holmquist F, Stief CG, Jonas U, Andersson KE (1991) Effects of the nitric oxide synthase
inhibitor NG-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the
rabbit. Acta Physiol Scand 143:299-304
Jacobsen SJ, Guess HA, Panser L, Girman CJ, Chute CG, Oesterling JE, Lieber MM (1993)
A population-based study of health care-seeking behaviour for treatment of urinary symptoms.
Arch Fam Med 2:729-735
Kalsi JS, Kell PD (2004) Update on the oral treatments for male erectile dysfunction. J Eur Acad
Dermatol Venereol 18:267-274
Kang KK, Yu JY, Yoo M, Kwon JW (2005) The effect of DA-8159, a novel PDE5 inhibitor, on erectile
function in the rat model of hypercholesterolemic erectile dysfunction. Int J Impot Res 17:409-416
Kaplan SA, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to
monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol
51:1717-1723
Kuhn R, Uckert S, Stief CG, Truss MC, Lietz B, Bischoff E, Schramm M, Jonas U (2000)
Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide
dependent pathways. Urol Res 28:110-115
Kuthe A, Magert HJ, Uckert S, Forssmann WG, Stief CG, Jonas U (2000) Gene expression of the
phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur Urol 38:108-114
Kuthe A, Wiedenroth A, Magert HJ, Uckert S, Forssmann WG, Stief CG, Jonas U (2001)
Expression of different phosphodiesterase genes in human cavernous smooth muscle. J Urol
165:280-283
Liguori G, Trombetta C, de Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G,
Bucci S, Belgrano E (2009) Efficacy and safety of combined oral therapy with tadalafil and
alfuzosin: an integrated approach to the management of patients with lower urinary tract
symptoms and erectile dysfunction. Preliminary report. J Sex Med 6:544-552
Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA (1999) Isolation and
characterization of PDE10A, a novel human 3'.5'-cyclic nucleotide phosphodiesterase. Gene
234:109-117
ulcer C, T
Search WWH ::




Custom Search